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Summary The Y haptenic blood group determinant is expressed on the cells of malignant gastrointestinal
tumours and on the normal gastrointestinal epithelium of individuals who can secrete blood group antigens.
An enzyme-linked immunosorbent assay incorporating the high affinity biotin-avidin interaction was
developed to measure the serum levels of antigens bearing the Y hapten in patients with colorectal cancer. The
specificity of the assays was between 88 and 93% and the sensitivity in detecting extensive disease was between
24 and 34%. However, up to 67% of patients with local or abdominal recurrent disease secreted antigens
expressing the Y hapten, whereas only 30% of patients with overt hepatic metastases secreted a similar
antigen. Recognition of antigens bearing the Y hapten may therefore be useful in detecting early local relapse
of colorectal cancer when a second operation to excise the recurrence may be possible.
There is considerable interest in non-invasive techniques for
the identification of patients with recurrent disease or liver
metastases following resection of primary colorectal tumours.
At present carcinoembyronic antigen (CEA) is used in pos-
toperative monitoring, in an attempt to detect early relapse.
However, Finlay and McArdle (1983) showed recurrence to
be identified by computerised tomography 7.5 months before
any increase in CEA was seen. There is an urgent require-
ment for detection of a new tumour associated antigen which
is secreted by a large percentage of early recurrent tumours,
or for identification of an antigen which would complement
CEA monitoring of recurrent disease.
The difucosylated type 2 carbohydrate chain associated
with the H blood group antigen is referred to as the Y
hapten. The monoclonal antibody C14, raised against extra-
nuclear membranes of a human colonic adenoma has been
shown to define the Y hapten (Brown et al., 1983). Using
C14, Brown et al. (1984) showed that 96% of colorectal
adenocarcinomas and 100% of adenomas expressed the Y
hapten. The expression was greater than that shown by any
normal colonic mucosa (Durrant et al., 1986). Although Y
hapten can be detected in saliva from individuals who are
blood group secretors, it is not known whether antigens
bearing the Y hapten are shed into the circulation. We have
developed a rapid accurate enzyme-linked immunosorbent
assay to screen for antigen bearing Y hapten in sera.
Materials and methods
Monoclonal antibody
C14 is an IgM monoclonal antibody which was purified from
mouse ascitic fluid on lentil lectin sepharose as previously
described (Takacs & Staehelin, 1981) and stored at a concen-
tration of 3.07 mg ml-' at -70°C. NCRC-21 is an IgM
monoclonal antibody which was raised against a colorectal
tumour glycolipid extract. It was subsequently found to react
with an epitope on a high molecular weight mucin which also
expressed the Y hapten (M.R. Price, unpublished results). It
was purified from mouse ascitic fluid on lentil lectin
sepharose as described above.
Immunoflourescence
The activity of the biotinylated C14 was tested by indirect
immunofluorescence on the colorectal cell line C170. Briefly,
2 x 106 cells were incubated at 4°C for 30 min with antibody
(10 gg) before washing and incubating with either FITC-
rabbit anti-mouse immunoglobulins (Dakopatts, Denmark)
or FITC streptavidin (Serotech, Bicester, UK). Both incuba-
tions were for 30 min at 4°C. The cells were washed before
analysis on a FACS IV using similar conditions to those
previously described (Durrant el al., 1986).
Biotinylation ofC14
Incubation of C14 monoclonal antibody with varying con-
centrations (30-120 Ig ml-') of N-hydroxysuccinamide
(NHS)-biotin (Guesden et al., 1979) for I h at 4°C in the
dark resulted in complete loss of antigen-antibody binding
(Table I).
Conjugation ofcertain macromolecules to NHS-biotin may
cause steric hindrance of the biotin-avidin interaction. The
use of a spacer arm limits this problem. C14 was therefore
labelled using a long chain derivative of NHS-biotin with a
13 atom spacer, arm, sulphosuccinimidyl-6-(biotin
amindo)hexanote (NHS-LC-biotin; Pierce, Illinois, USA).
Freshly prepared NHS-LC biotin was dissolved in
dimethylformamide (2 mg ml') and added (60-120 gg per
I mg of antibody) to C14 monoclonal antibody in sodium
bicarbonate buffer at pH 9.0. The reaction was stirred gently
in the dark for I h. Biotinylated antibody was separated from
free NHS-LC-biotin on a PD-10 column, when NHS-LC-
biotin was used at concentration of 60 lag ml-' it resulted in
retention of antibody binding (Table I) and good levels of
biotinylation (Table I). The lower mean fluorescence
obtained using streptavidin-FITC compared to rabbit anti-
mouse-FITC were due to differing binding ratios. Each biotin
molecule can bind only one streptavidin FITC whereas each
mouse antibody can bind two to three rabbit anti-mouse
antibodies. There are two to three molecules of fluorescein
Table I Indirect immunofluorescence of biotinylated C14 on
C170 colorectal cancer cells
Primary antibody Mean fluorescence
C14 8806 7c
nMse IgM 11 6
NHS-biotinylated
C14b (30)d 14 12
C14b (60) 10 14
CI4b (I120) 20 8
NHS-LC-biotinylated
C14b (60) 403 192
C14b (120) 87 12
"Primary antibody (10glg per 2 x 106 cells) as specified. bSecondary
antisera was FITC-conjugated Rabbit anti-mouse (1.40). cSecondary
reagent streptavidin-FITC (1:400). dFigures in parenthesis refer to
concentrations of NHS-biotin or NHS-LC biotin which were used in
the original biotinylations.
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isothiocyanate attached to each streptavidin or antibody
molecule. As the mean fluorescence obtained with C14 biotin
recognised by FITC conjugate rabbit anti-mouse sera was
twice the value obtained with streptavidin FITC it suggests
that only one biotin molecule per C14 antibody molecule was
available to recognise streptavidin-FITC. Increasing the dose
of NHS-LC-biotin to attach more molecules of biotin
resulted in a large loss of binding activity (Table I) as did
increasing the incubation time (data not shown).
ELISA to detect C14 defined antigen
C14 (500 ng per well) or NCRC-21 (500 ng per well) was
added to flexible microtest plates (Falcon, Becton Dickinson,
Oxnoid, CA, USA) and left at 4°C overnight. The plates were
washed three times with phosphate buffered saline containing
0.05% Tween 20 (PBS-Tween) and blocked with BSA (10%)
for I h at room temperature. The plate was washed three
times, then serial dilutions of saliva or sera in a buffer at
pH 3.0 (5 g BSA, 50 nmol sodium citrate, I mmol EDTA in 1
litre of H20) were added. After I h at room temperature the
plates were washed five times in PBS-Tween and biotinylated
C14 (500 ng per well) was added. Following incubation at
room temperature for 1 h and washing five times, avidin
alkaline phosphatase (Sigma, UK) diluted 1:400 was added
for a further I h. Finally, after extensive washing the plates
were developed with P-nitrophenol phosphate (Sigma, UK)
and read at 405 nm.
Radioimmunoassaysfor the detection ofcarcinoembryonic
antigen and CA19-9 antigen
Carcinoembryonic antigen (CEA) was estimated using a com-
mercially available radioimmunoassay kit (Serona Labs)
based on a polyclonal antibody to CEA. Ten gg 1' was
defined as positive. CA19-9 was measured using a commer-
cially available solid phase radioimmunoassay (CIS UK Ltd,
London). Thirty-three units ml-' was defined as positive.
Sera samples
The sera of 55 patients with extensive colorectal carcinomas
were tested for the presence of an antigen bearing the Y
hapten. Of these patients, 36 had liver metastases, one had
lung and brain metastases and 15 had pelvic or abdominal
recurrent disease including five patients who had both liver
metastases and recurrence and three had second primaries.
Forty-three samples from normal subjects with no bowel
symptoms were also screened.
The absorbence at 405 nm (A405) of the positive results was
converted into units ml-' as follows using the saliva from
one secretor as a standard.
A405 standard saliva - A405 buffer alone = 10 units
(under constant conditions)
A405 sample - A405 buffer
x 10 units in 50g1
A405 standard saliva - A45 buffer alone
Units in 50til x 20 = units of Y haptenic blood group deter-
minant ml-'. Buffer alone plus two standard deviations never
exceeded 20 units ml-' for detection by C14 biotin and 50
units ml1 for detection by NCRC-21 biotin. These levels
were therefore the values for positive results.
Results
Development of the ELISA for detection of C14
The ELISA assays depend upon either recognition of the
Y hapten on an antigen by the solid phase capturing C14
antibody or recognition of the NCRC-21 defined epitope on
an antigen and then recognition of the Y hapten on these
antigens by the biotinylated C14. Initial assays performed on
saliva from normal individuals including blood group
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Figure 1 Expression of an antigen expressing the Y haptenic
blood group in sera and saliva of normal individuals as recog-
nised by the antibodies C14(a) and NCRC-21(b). The line
represents the mean units + 2 standard deviations of buffer alone
and has been used for defining positive values.
secretors confirmed that antigens bearing two Y haptens or
an NCRC-21 epitope and a Y hapten existed (Figure 1).
However, when the serum from normal individuals was
screened (Figure 1), sera from 3/43 (7%) normal donors gave
a positive result with the C14 capturing antibody (Figure 1).
Only one of these positive sera was from an individual with
antigen in his saliva.
Sera from 34% of the patients with colorectal cancer gave
positive results when C14 was the capturing antibody (Figure
2). However, 67% of the patients with pelvic or abdominal
recurrent disease secreted antigen bearing the Y hapten into
their serum compared with 30% of patients with metastases
were positive (X2 = 4.6;0.05>P>0.02). Five patients had
both liver metastases and recurrent disease. Of these three
showed positive results and two were negative. If these
patients are excluded from the total patient analysis 70% of
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patients with only recurrent disease and 28% of patients with
metastases alone are positive. Antigen captured by NCRC-21
monoclonal antibody was detected in 24% of patients sera.
Thirty-three per cent of patients with recurrent disease exp-
ressed this antigen and 22% of patients with metastases
(Figure 2).
There was no correlation between expression of the
antigen(s) captured by C14 and those captured by NCRC-21
(Figure 3). Seven patients secreted an antigen expressing two
Y haptenic determinants but no NCRC-21 defined antigen
whereas one patient expressed the NCRC-21 defined antigen
but did not express two accessible Y haptenic determinants.
Furthermore, there was no correlation between the expres-
sion ofCEA, CAI9-9 and the two types ofantigen defined in
these assays (Figure 3).
CEA was still the most sensitive monitor of metastatic
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Figure 2 Expression of an antigen expressing the Y haptenic blood group in a sera of patients with colorectal cancer as recognised
by the antibodies C14(a) and NCRC-21(b). P, all patients tested; M, patients with overt liver metastases; R, patients with recurrent
disease. The line represents the mean units + 2 standard deviations of buffer alone and has been used for defining positive values.
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Figure 3 Correlations between the levels of antigen expressing the Y haptenic blood group in sera of patients with colorectal
cancer and the levels of carcinoembryonic antigen (CEA) and levels of CA19-9 antigen.
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disease as 73% of these patients had elevated levels of this
antigen. The sensitivity of detection of recurrent disease is
similar for CEA and C14 assays. However, detection of both
recurrence and metastatic disease can be increased to 80%
and 82%, if CEA assays are combined with C14 and NCRC-
21 ELISAs. Similarly, the sensitivity of the CA19-9 assay in
detecting recurrent disease can be doubled by also screening
by C14 and NCRC-21 ELISAs (Table II).
Table 11 Sensitivities of the tests for CEA, CA19-9 and Y hapten
(using C14 and NCRC-21 as the catching antibody)
Sera from
Sera from patients
recurrent with
All sera patients metastases
Test + vea 5% + ve S% +ve S%
C14 19/55 34 10/15 67 6/22 27
NCRC-21 13/55 24 5/15 33 4/22 18
CEA 23/36 64 10/15 67 16/22 73
CAl9-9 14/35 40 6/15 40 11/22 50
C14 & NCRC-21 21/55 38 10/15 67 7/22 32
CEA & CAl9-9 26/35 74 11/15 73 18/22 82
C14 & NCRC-21 & CEA 28/36 78 12/15 80 18/22 82
C14 & NCRC-21 23/36 64 12/15 80 13/22 59
CA19-9
C14 & NCRC-21 & CEA & 29/36 81 12/15 80 19/22 86
CA19-9
a + ve, percentage of samples positive. bS%, sensitivity.
Discussion
The Y haptenic blood group determinant is known to be
expressed by malignant gastrointestinal cells (Brown et al.,
1984; Lloyd et al., 1983; Abe et al., 1986). This project shows
that it is also released into the circulation in up to 33% of
patients with extensive colorectal cancer.
RIA have previously been used in the detection of cir-
culating tumour-associated antigens. The ELISA developed
in this study presents many advantages over the RIA. Since
no radioisotopes are used the ELISA is less hazardous and
can be perfomred in any laboratory without the need for
expensive gamma-counters. Radiolabelled antibody remains
stable for only 1-2 months, whereas biotinylated antibody
can be stored for an indefinite period. A large batch of
antibody can be biotinylated and used in numerous assays,
thereby allowing results to be reproducible.
Brown et al. (1984) showed that the Y hapten was strongly
expressed on the normal gastrointestinal epithelia of in-
dividuals of secretor status while being weak or absent in
non-secretors. Of the normal individuals tested 11/13 were
secretors but only one of these expressed Y hapten bearing
antigens in the serum. It would appear that the antigen is not
released generally into the circulation from normal gast-
rointestinal cells. All antigens detected by the assays in this
study must carry a Y haptenic blood group determinant.
There may, however, be several discrete antigens carrying
this specific epitope. An antigen carrying a minimum of two
Y haptenic blood group determinant and an epitope recog-
nised by NCRC-21 would give a positive result using NCRC-
21 as the catching antibody. A third possibility is that in
addition to there being these two different types of antigen,
there is a third type which carries both an NCRC-21 epitope
and two or more Y haptenic blood group determinants.
Seven patients secreted an antigen recognised by two C14
antibody molecules but failed to bind to NCRC-21 and one
patient secreted an antigen which bound to NCRC-21 and
C14 but not to two C14 antibody molecules. These results
suggest that at least two discrete antigens are being detected
by the ELISA assays.
Thirty-four per cent of colorectal cancer patients with
extensive disease secreted an antigen recognised by two C14
molecules and 24% an antigen recognised by C14 and
NCRC-21. This sensitivity is low compared to CEA (64%)
but similar to that seen for secretion of CA19-9 antigen
(40%). However, there was no obvious correlation between
expression of any of the antigens and in fact co-screening for
all four antigens improved the sensitivity of recurrent cancer
detection to 80%.
C14 shows a sensitivity of 67% for patients with recur-
rence and only a 30% sensitivity for patients with metastases,
whereas CEA showed a similar sensitivity for both groups of
patients and CA19-9 showed an elevated sensitivity in
patients with overt hepatic metastases. This suggests that C14
could prove to be of clinical value in detecting recurrence
that is potentially curable by second operations. This is
particularly important in view of the fact that serum CEA
levels are related to tumour bulk and therefore raised levels
often occur when recurrence is beyond cure and liver meta-
stases are present (Finlay & McArdle, 1983). Despite a
number of encouraging reports showing CEA to have a high
sensitivity for recurrence (reviewed by Northover, 1986), its
late stage expression (Finlay & McArdle, 1983) and its high
false negative rate of approximately 20% (Herrera et al.,
1976; Wood et al., 1980) suggest its clinical value in detecting
early recurrences is limited.
A further study including serum samples from a large
age-matched normal panel, patients with inflammatory
diseases, ademomatous polyps, primary cancer, recurrent
disease and liver metastases is currently in progress. A pro-
spective study to determine if this assay can detect recurrence
earlier than other methods and hence improve treatment is
also ongoing. However, these results are encouraging in view
of the fact that no other tumour antigen has been reported to
be expressed more by recurrent disease than by liver meta-
stases. Antigens expressing the Y hapten may be useful in
identifying patients with early potentially curable recurrent
disease.
This work was funded by a grant from the Cancer Research Cam-
paign.
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